PE20020772A1 - Composicion farmaceutica que comprende una molecula ctla4 soluble - Google Patents
Composicion farmaceutica que comprende una molecula ctla4 solubleInfo
- Publication number
- PE20020772A1 PE20020772A1 PE2001001131A PE2001001131A PE20020772A1 PE 20020772 A1 PE20020772 A1 PE 20020772A1 PE 2001001131 A PE2001001131 A PE 2001001131A PE 2001001131 A PE2001001131 A PE 2001001131A PE 20020772 A1 PE20020772 A1 PE 20020772A1
- Authority
- PE
- Peru
- Prior art keywords
- ctla4
- pharmaceutical composition
- soluble
- sulfasal
- molecula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: i)DE 0,5mg/Kg A 100mg/Kg DE UNA MOLECULA MUTADA DE LA PROTEINA CTL4 EN LA POSICION +104, QUE CAMBIA LA LEUCINA POR OTRO AMINOACIDO SIENDO LA MOLECULA SOLUBLE DE CTLA4 1)L104EIg DE 357 AMINOACIDOS; 2)UNA MUTACION EN LA POSICION 104 DE CTLA4 (LEUCINA POR ACIDO GLUTAMICO); UNA SEGUNDA MUTACION POR CUALQUIER OTRO AMINOACIDO DE a)ALANINA EN LA POSICION 29; b)GLICINA EN LA POSICION 105; c)SERINA EN LA POSICION 25; d)TREONINA EN LA POSICION 32; 3)L104EA29YIg; 4)L104EA29LIg; 5)L104EA29TIg; 6)L104EA29WIg; Y ii)UN AGENTE INMUNOSUPRESOR COMO CORTICOSTEROIDES, ANTIINFLAMATORIOS NO ESTEROIDALES, CICLOSPORINA, PREDNISONA, AZATIOPRINA, METOTREXATO, BLOQUEADORES O ANTAGONISTAS DE TNFa, INFLIXIMAB, SULFASALOZOPRINA, SALES DE ORO, ETANERCEPT, ANAKINRA; iii)PORTADOR FARMACEUTICAMENTE ACEPTABLE COMO INTERCAMBIADORES DE IONES, ALUMINA, ESTEARATO DE ALUMINIO, LECITINA, PROTEINAS SERICAS, , SUSTANCIAS AMORTIGUADORAS, GLICINA, ACIDO ASCORBICO, SORBATO DE POTASIO, SILICE COLOIDAL. LAS MOLECULAS MUTADAS CTLA4 SOLUBLES BLOQUEAN QUE LAS MOLECULAS B7 ENDOGENAS SE ENLACEN A SUS LIGANDOS CD28 EN LAS CELULAS T Y PUEDEN SER UTIL PARA EL TRATAMIENTO DE ENFERMEDADES REUMATICAS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21591300P | 2000-07-03 | 2000-07-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20020772A1 true PE20020772A1 (es) | 2002-09-06 |
Family
ID=22804919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2001001131A PE20020772A1 (es) | 2000-07-03 | 2001-11-14 | Composicion farmaceutica que comprende una molecula ctla4 soluble |
Country Status (39)
Country | Link |
---|---|
US (1) | US7455835B2 (es) |
EP (4) | EP3384924A1 (es) |
JP (1) | JP2004517806A (es) |
KR (3) | KR100895552B1 (es) |
CN (1) | CN1318086C (es) |
AR (2) | AR035037A1 (es) |
AT (1) | ATE401909T1 (es) |
AU (2) | AU7317401A (es) |
BG (2) | BG66024B1 (es) |
BR (1) | BR0112104A (es) |
CA (2) | CA2630062C (es) |
CY (3) | CY1109786T1 (es) |
CZ (1) | CZ303959B6 (es) |
DE (1) | DE60135029D1 (es) |
DK (2) | DK1372696T3 (es) |
EE (1) | EE05378B1 (es) |
ES (2) | ES2667203T3 (es) |
HK (1) | HK1058486A1 (es) |
HR (1) | HRP20030071B1 (es) |
HU (3) | HU227669B1 (es) |
IL (2) | IL153593A0 (es) |
IS (1) | IS2834B (es) |
LT (2) | LT1935427T (es) |
LV (1) | LV12993B (es) |
MX (1) | MXPA02012603A (es) |
MY (1) | MY137552A (es) |
NO (3) | NO20026264L (es) |
PE (1) | PE20020772A1 (es) |
PL (2) | PL207534B1 (es) |
PT (2) | PT1372696E (es) |
RS (1) | RS50811B (es) |
RU (1) | RU2287340C2 (es) |
SI (3) | SI21078A (es) |
SK (1) | SK287940B6 (es) |
TR (1) | TR201807700T4 (es) |
TW (2) | TWI322153B (es) |
UY (1) | UY26815A1 (es) |
WO (1) | WO2002002638A2 (es) |
ZA (1) | ZA200210058B (es) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6887471B1 (en) * | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
JP4751493B2 (ja) * | 1996-03-20 | 2011-08-17 | ブリストル−マイヤーズ スクイッブ カンパニー | Gp39/cd40およびctla4/cd28/b7経路のブロックによって免疫反応を阻止する方法およびそれに使用する組成物 |
US20030219863A1 (en) * | 1997-01-31 | 2003-11-27 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
ZA98533B (en) * | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
AU2001263466C1 (en) * | 2000-05-26 | 2006-10-26 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
KR20030007899A (ko) * | 2000-06-09 | 2003-01-23 | 브리스톨-마이어스스퀴브컴파니 | 림프구성 신호의 차단 및 lfa-1 매개 접착의 차단을통한 세포-매개 면역 반응의 조절 방법 |
US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
TWI322153B (en) * | 2000-07-03 | 2010-03-21 | Bristol Myers Squibb Co | Methods for treating rheumatic diseases using a soluble ctla4 molecule |
HUP0303930A3 (en) * | 2001-01-26 | 2012-09-28 | Univ Emory | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
DE60225914T2 (de) | 2001-05-23 | 2009-07-23 | Bristol-Myers Squibb Co. | Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4-mutationsmolekülen |
CA2482042A1 (en) * | 2002-04-19 | 2003-10-30 | Bristol-Myers Squibb Company | Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid |
US7541164B2 (en) * | 2002-12-23 | 2009-06-02 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
BR0316882A (pt) * | 2002-12-23 | 2005-10-25 | Bristol Myers Squibb Co | Melhora na qualidade de produtos em processos de cultura de células de mamìferos para a produção de proteìnas |
CA2511823A1 (en) | 2002-12-30 | 2004-07-22 | Amgen Inc. | Combination therapy with co-stimulatory factors |
CN1863546A (zh) * | 2003-08-04 | 2006-11-15 | 布里斯托尔-迈尔斯.斯奎布公司 | 用可溶性ctla4分子治疗心血管疾病的方法 |
AU2004287431B2 (en) | 2003-10-27 | 2010-03-11 | Amgen Inc. | Compositions and methods to modulate an immune response to an immunogenic therapeutic agent |
US7815765B2 (en) * | 2004-04-01 | 2010-10-19 | Swei Mu Wang | Method for forming laminated synthetic leather |
US9309316B2 (en) | 2005-12-20 | 2016-04-12 | Bristol-Myers Squibb Company | Stable subcutaneous protein formulations and uses thereof |
AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
PT1969007E (pt) * | 2005-12-20 | 2013-12-10 | Bristol Myers Squibb Co | Composições e métodos para a produção de uma composição |
WO2007076354A2 (en) * | 2005-12-20 | 2007-07-05 | Bristol-Myers Squibb Company | Stable protein formulations |
US7528111B2 (en) * | 2006-05-12 | 2009-05-05 | Bristol-Myers Squibb Company | Method of vaccinating subjects receiving immune modulating therapy |
GB0620934D0 (en) * | 2006-10-20 | 2006-11-29 | Cambridge Antibody Tech | Protein variants |
AU2012202324B2 (en) * | 2007-11-01 | 2014-08-28 | Astellas Pharma Inc. | Immunosuppressive polypeptides and nucleic acids |
US7794718B2 (en) * | 2007-11-01 | 2010-09-14 | Perseid Therapeutics, LLC | Immunosuppressive polypeptides and nucleic acids |
AU2014250683B2 (en) * | 2007-11-01 | 2015-11-26 | Astellas Pharma Inc. | Immunosuppressive polypeptides and nucleic acids |
US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
US7915222B2 (en) * | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
WO2010033878A2 (en) | 2008-09-19 | 2010-03-25 | David Brown | Solute concentration measurement device and related methods |
WO2010042433A1 (en) | 2008-10-06 | 2010-04-15 | Bristol-Myers Squibb Company | Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases |
RU2506311C2 (ru) * | 2008-10-30 | 2014-02-10 | Йеда Рисёрч Энд Девелопмент Ко. Лтд. | Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний |
WO2011014704A2 (en) | 2009-07-30 | 2011-02-03 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
CN102030828B (zh) * | 2009-09-25 | 2014-10-29 | 上海抗体药物国家工程研究中心有限公司 | 一种高亲和力的CTLA4-Ig融合蛋白突变体 |
CN106432473B (zh) * | 2010-02-19 | 2021-04-02 | Xencor公司 | 新颖ctla4-ig免疫粘附素 |
TW201134481A (en) * | 2010-03-12 | 2011-10-16 | Abbott Biotherapeutics Corp | CTLA4 proteins and their uses |
US9527912B2 (en) | 2010-05-17 | 2016-12-27 | The Board Of Trustees Of The Leland Stanford Junior University | Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade |
SG188471A1 (en) | 2010-09-08 | 2013-04-30 | Yeda Res & Dev | An immunosuppressive drug combination for a stable and long term engraftment |
PT2613801T (pt) | 2010-09-08 | 2016-09-12 | Yeda Res & Dev | Utilização de células t de memória central anti-terceiros no tratamento anti-leucemia/linfoma |
WO2013010537A1 (en) * | 2011-07-20 | 2013-01-24 | Aarhus Universitet | Method of treating morphea |
WO2013035099A1 (en) | 2011-09-08 | 2013-03-14 | Yeda Research And Development Co. Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
US8735359B2 (en) | 2012-05-24 | 2014-05-27 | Orban Biotech Llc | Combinations of modalities for the treatment of diabetes |
US9555186B2 (en) | 2012-06-05 | 2017-01-31 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
AU2013284460A1 (en) | 2012-06-27 | 2015-01-29 | Dmnomore | CTLA4 fusion proteins for the treatment of diabetes |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
WO2014151230A2 (en) | 2013-03-15 | 2014-09-25 | Bristol-Myers Squibb Company | Method of treating granulomatosis with polyangiitis |
CN104740608A (zh) * | 2013-12-30 | 2015-07-01 | 上海中信国健药业股份有限公司 | 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途 |
GB2523399B (en) | 2014-02-25 | 2019-03-13 | Orban Tihamer | A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence |
CN106456712A (zh) | 2014-04-25 | 2017-02-22 | 百时美施贵宝公司 | Ctla4化合物用于在具有早期ra的受试者中实现无药物缓解的用途 |
SI3283508T1 (sl) | 2015-04-17 | 2021-09-30 | Alpine Immune Sciences, Inc. | Imunomodulirajoči proteini z nastavljivimi afinitetami |
ES2963038T3 (es) | 2015-07-16 | 2024-03-25 | Yeda Res & Dev | Uso de células T de memoria central antitercero |
EP3192805A1 (en) | 2016-01-15 | 2017-07-19 | Humanitas Mirasole S.p.A. | Inhibitors of t cell activation or stimulation and uses thereof |
MA43552A (fr) | 2016-04-15 | 2018-11-07 | Alpine Immune Sciences Inc | Protéines immunomodulatrices à variants de cd80 et leurs utilisations |
CN110392736A (zh) | 2017-01-18 | 2019-10-29 | 耶达研究及发展有限公司 | 遗传修饰的反抑细胞及其在免疫治疗中的用途 |
US10751368B2 (en) | 2017-01-18 | 2020-08-25 | Yeda Research And Development Co. Ltd. | Methods of transplantation and disease treatment |
JP2020536552A (ja) | 2017-10-10 | 2020-12-17 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ctla−4変異型免疫調節タンパク質およびそれらの使用 |
EA202090974A1 (ru) | 2017-10-18 | 2020-08-05 | Элпайн Иммьюн Сайенсиз, Инк. | Вариантные иммуномодулирующие белки лиганда icos и сопутствующие композиции и способы |
WO2019175384A2 (en) | 2018-03-16 | 2019-09-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes |
EP3765064A1 (en) | 2018-03-16 | 2021-01-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes |
EP3765065A2 (en) | 2018-03-16 | 2021-01-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes |
US20220098264A1 (en) | 2019-01-15 | 2022-03-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy |
WO2023112992A1 (ja) * | 2021-12-16 | 2023-06-22 | レグセル株式会社 | 免疫系の異常に関連する疾患、障害または症状を処置するための医薬組成物 |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US644792A (en) * | 1899-09-14 | 1900-03-06 | Stanhope Boal | Heater. |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
DE3424893A1 (de) | 1984-07-06 | 1986-02-06 | Agfa-Gevaert Ag, 5090 Leverkusen | Photographisches silberhalogenidaufzeichnungsmaterial |
US6685941B1 (en) * | 1988-11-23 | 2004-02-03 | The Regents Of The University Of Michigan | Methods of treating autoimmune disease via CTLA-4Ig |
CA2003455C (en) * | 1988-11-23 | 2000-02-22 | Craig B. Thompson | Immunotherapy involving cd28 stimulation |
US6905680B2 (en) * | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US6352694B1 (en) * | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US5858358A (en) * | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6641809B1 (en) * | 1990-03-26 | 2003-11-04 | Bristol-Myers Squibb Company | Method of regulating cellular processes mediated by B7 and CD28 |
US7070776B1 (en) * | 1990-03-26 | 2006-07-04 | Bristol-Myers Squibb Company | Methods for blocking binding of CD28 receptor to B7 |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
AU661854B2 (en) | 1991-06-27 | 1995-08-10 | Bristol-Myers Squibb Company | CTL4A receptor, fusion proteins containing it and uses thereof |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US5770197A (en) | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
US6090914A (en) * | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US5624823A (en) * | 1991-11-22 | 1997-04-29 | The General Hospital Corporation | DNA encoding procine interleukin-10 |
US5958403A (en) | 1992-02-28 | 1999-09-28 | Beth Israel Hospital Association | Methods and compounds for prevention of graft rejection |
JPH07508711A (ja) | 1992-04-07 | 1995-09-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Cd28経路免疫調節 |
US5747034A (en) * | 1992-07-09 | 1998-05-05 | Chiron Corporation | Methods and materials for the induction of T cell anergy |
US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
US5773253A (en) | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
DK0700430T3 (da) | 1993-06-04 | 2005-08-15 | Us Navy | Fremgangsmåder til selektivt af stimulere proliferation af T-celler |
AU7107794A (en) | 1993-06-10 | 1995-01-03 | Regents Of The University Of Michigan, The | Cd28 pathway immunosuppression |
AU696235B2 (en) | 1993-09-02 | 1998-09-03 | Bristol-Myers Squibb Company | Anti-GP39 antibodies and uses therefor |
CN1142765A (zh) | 1993-12-01 | 1997-02-12 | 三共株式会社 | 以聚戊二烯基衍生物作为有效成分的炎症性细胞素产生抑制剂 |
US5683693A (en) | 1994-04-25 | 1997-11-04 | Trustees Of Dartmouth College | Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40 |
US6719972B1 (en) * | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
JPH10504703A (ja) | 1994-06-03 | 1998-05-12 | アメリカ合衆国 | T細胞の選択的刺激増殖方法 |
JPH10501815A (ja) | 1994-06-07 | 1998-02-17 | リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ | 抗原特異的t細胞応答の阻害方法 |
US5634055A (en) * | 1994-09-27 | 1997-05-27 | Bidplus, Inc. | Method for selecting assignments |
WO1996014865A1 (en) | 1994-11-10 | 1996-05-23 | Repligen Corporation | Methods for inhibiting graft versus host disease in bone marrow transplantation |
US5876950A (en) | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
US5824655A (en) | 1995-02-15 | 1998-10-20 | The University Of Utah | Anti-transforming growth factor-β gene therapy |
US5993800A (en) | 1995-06-05 | 1999-11-30 | Bristol-Myers Squibb Company | Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand |
US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
US6750334B1 (en) * | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
JP4751493B2 (ja) * | 1996-03-20 | 2011-08-17 | ブリストル−マイヤーズ スクイッブ カンパニー | Gp39/cd40およびctla4/cd28/b7経路のブロックによって免疫反応を阻止する方法およびそれに使用する組成物 |
JPH1067653A (ja) * | 1996-06-17 | 1998-03-10 | Eisai Co Ltd | 関節疾患治療剤 |
US6495579B1 (en) * | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
KR19980066046A (ko) | 1997-01-18 | 1998-10-15 | 정용훈 | 고역가의 CTLA4-Ig 융합단백질 |
US20030219863A1 (en) * | 1997-01-31 | 2003-11-27 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
ZA98533B (en) * | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
EP1009432A4 (en) | 1997-06-11 | 2004-07-07 | Us Navy | COMPOSITION AND METHOD FOR PREVENTING GRAFT REJECTS OR OTHER NON-ADAPTIVE T-LYMPHOCYTE IMMUNE RESPONSES |
EP0947524A1 (en) * | 1998-03-30 | 1999-10-06 | Upither B.V. | Novel peptides for the treatment of autoimmune diseases |
AU2999199A (en) * | 1998-04-03 | 1999-10-25 | Osiris Therapeutics, Inc. | Mesenchymal stem cells as immunosuppressants |
CA2333726A1 (en) * | 1998-06-05 | 1999-12-09 | Supergen, Inc. | Compositions comprising methotrexate and pentostatin for treating rheumatoid arthritis |
JP2000086519A (ja) * | 1998-09-17 | 2000-03-28 | Mitsui Chemicals Inc | 抗リウマチ薬効果増強剤 |
IL126681A0 (en) | 1998-10-21 | 1999-08-17 | Opperbas Holding Bv | Treatment of trauma-related conditions |
US6040292A (en) * | 1999-06-04 | 2000-03-21 | Celtrix Pharmaceuticals, Inc. | Methods for treating diabetes |
US7034121B2 (en) | 2000-01-27 | 2006-04-25 | Genetics Institue, Llc | Antibodies against CTLA4 |
AU2001264936A1 (en) | 2000-05-23 | 2001-12-03 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the ctla4 gene |
US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
AU2001263466C1 (en) | 2000-05-26 | 2006-10-26 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
KR20030007899A (ko) * | 2000-06-09 | 2003-01-23 | 브리스톨-마이어스스퀴브컴파니 | 림프구성 신호의 차단 및 lfa-1 매개 접착의 차단을통한 세포-매개 면역 반응의 조절 방법 |
TWI322153B (en) * | 2000-07-03 | 2010-03-21 | Bristol Myers Squibb Co | Methods for treating rheumatic diseases using a soluble ctla4 molecule |
US20040022787A1 (en) * | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
HUP0303930A3 (en) * | 2001-01-26 | 2012-09-28 | Univ Emory | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
DE60225914T2 (de) * | 2001-05-23 | 2009-07-23 | Bristol-Myers Squibb Co. | Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4-mutationsmolekülen |
-
2001
- 2001-07-02 TW TW097137769A patent/TWI322153B/zh not_active IP Right Cessation
- 2001-07-02 TR TR2018/07700T patent/TR201807700T4/tr unknown
- 2001-07-02 EP EP18158752.8A patent/EP3384924A1/en not_active Withdrawn
- 2001-07-02 KR KR1020087019039A patent/KR100895552B1/ko active Protection Beyond IP Right Term
- 2001-07-02 AU AU7317401A patent/AU7317401A/xx active Pending
- 2001-07-02 KR KR1020087005505A patent/KR100864120B1/ko active IP Right Grant
- 2001-07-02 UY UY26815A patent/UY26815A1/es not_active Application Discontinuation
- 2001-07-02 DK DK01952420T patent/DK1372696T3/da active
- 2001-07-02 SI SI200120046A patent/SI21078A/sl not_active IP Right Cessation
- 2001-07-02 AR ARP010103156A patent/AR035037A1/es active IP Right Grant
- 2001-07-02 AT AT01952420T patent/ATE401909T1/de active
- 2001-07-02 RS YUP-1011/02A patent/RS50811B/sr unknown
- 2001-07-02 AU AU2001273174A patent/AU2001273174B2/en not_active Expired
- 2001-07-02 US US09/898,195 patent/US7455835B2/en not_active Expired - Lifetime
- 2001-07-02 TW TW090116137A patent/TWI311564B/zh not_active IP Right Cessation
- 2001-07-02 EP EP10184596.4A patent/EP2281568A3/en not_active Withdrawn
- 2001-07-02 BR BR0112104-9A patent/BR0112104A/pt not_active Application Discontinuation
- 2001-07-02 JP JP2002507889A patent/JP2004517806A/ja active Pending
- 2001-07-02 KR KR10-2003-7000018A patent/KR20030017606A/ko active Application Filing
- 2001-07-02 SI SI200130864T patent/SI1372696T1/sl unknown
- 2001-07-02 CA CA2630062A patent/CA2630062C/en not_active Expired - Lifetime
- 2001-07-02 IL IL15359301A patent/IL153593A0/xx unknown
- 2001-07-02 CZ CZ20024261A patent/CZ303959B6/cs not_active IP Right Cessation
- 2001-07-02 SK SK1774-2002A patent/SK287940B6/sk not_active IP Right Cessation
- 2001-07-02 EE EEP200300004A patent/EE05378B1/xx active Protection Beyond IP Right Term
- 2001-07-02 HU HU0900660A patent/HU227669B1/hu unknown
- 2001-07-02 ES ES08001340.2T patent/ES2667203T3/es not_active Expired - Lifetime
- 2001-07-02 MY MYPI20013159A patent/MY137552A/en unknown
- 2001-07-02 CA CA002413190A patent/CA2413190C/en not_active Expired - Lifetime
- 2001-07-02 SI SI200131067T patent/SI1935427T1/en unknown
- 2001-07-02 WO PCT/US2001/021204 patent/WO2002002638A2/en active Application Filing
- 2001-07-02 PT PT01952420T patent/PT1372696E/pt unknown
- 2001-07-02 HU HU0301727A patent/HU226847B1/hu active Protection Beyond IP Right Term
- 2001-07-02 PT PT80013402T patent/PT1935427T/pt unknown
- 2001-07-02 LT LTEP08001340.2T patent/LT1935427T/lt unknown
- 2001-07-02 PL PL365942A patent/PL207534B1/pl unknown
- 2001-07-02 CN CNB018122299A patent/CN1318086C/zh not_active Expired - Lifetime
- 2001-07-02 ES ES01952420T patent/ES2310557T3/es not_active Expired - Lifetime
- 2001-07-02 DK DK08001340.2T patent/DK1935427T3/en active
- 2001-07-02 RU RU2003103098/14A patent/RU2287340C2/ru active
- 2001-07-02 EP EP08001340.2A patent/EP1935427B1/en not_active Expired - Lifetime
- 2001-07-02 DE DE60135029T patent/DE60135029D1/de not_active Expired - Lifetime
- 2001-07-02 PL PL389002A patent/PL212205B1/pl unknown
- 2001-07-02 MX MXPA02012603A patent/MXPA02012603A/es active IP Right Grant
- 2001-07-02 EP EP01952420A patent/EP1372696B1/en not_active Expired - Lifetime
- 2001-11-14 PE PE2001001131A patent/PE20020772A1/es not_active Application Discontinuation
-
2002
- 2002-12-06 BG BG107362A patent/BG66024B1/bg unknown
- 2002-12-11 ZA ZA2002/10058A patent/ZA200210058B/en unknown
- 2002-12-23 IL IL153593A patent/IL153593A/en active IP Right Grant
- 2002-12-27 NO NO20026264A patent/NO20026264L/no not_active Application Discontinuation
-
2003
- 2003-01-02 IS IS6667A patent/IS2834B/is unknown
- 2003-01-07 LT LT2003002A patent/LT5063B/lt not_active IP Right Cessation
- 2003-02-03 LV LVP-03-08A patent/LV12993B/en unknown
- 2003-02-03 HR HRP20030071AA patent/HRP20030071B1/hr not_active IP Right Cessation
-
2004
- 2004-02-25 HK HK04101364.2A patent/HK1058486A1/xx not_active IP Right Cessation
-
2008
- 2008-05-09 AR ARP080101975A patent/AR066511A2/es unknown
- 2008-10-21 CY CY20081101167T patent/CY1109786T1/el unknown
- 2008-11-05 CY CY2008017C patent/CY2008017I2/el unknown
-
2010
- 2010-03-05 BG BG110611A patent/BG66454B1/bg unknown
- 2010-04-22 NO NO20100580A patent/NO20100580L/no not_active Application Discontinuation
- 2010-04-22 NO NO20100579A patent/NO20100579L/no unknown
- 2010-04-27 HU HUS1000008C patent/HUS1000008I1/hu unknown
-
2018
- 2018-05-23 CY CY20181100546T patent/CY1120577T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20020772A1 (es) | Composicion farmaceutica que comprende una molecula ctla4 soluble | |
EA200000331A1 (ru) | Фармацевтические композиции, содержащие белок плазмы | |
BG101841A (en) | Cellular adhesion inhibitors | |
WO2002048183A3 (en) | Compositions of peptide crystals | |
PT1311285E (pt) | Composicao farmaceutica liquida contendo um derivado de eritropoietina | |
DK0661989T3 (da) | Proteinsammensætninger med vedvarende frigivelse | |
CO5050400A1 (es) | Proteina de chlamydia, secuencia de genes y anticuerpos para ello | |
ES2157994T3 (es) | Inhibidores tetra y pentapeptidos sustituidos de la proteina farnesiltransferasa. | |
LU91680I2 (fr) | "rilonacept et ses dérivés pharmaceutiquement acceptables (ARCALYSR)" | |
NO20043891L (no) | Anti-A-beta-antistoffer og deres anvendelse | |
IL195338A (en) | An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use | |
HK1036994A1 (en) | Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof | |
DE69732640D1 (de) | Festphasen-peptidsynthese | |
TR200000927T2 (tr) | Prostaglandin agonistleri ve kemik bozukluklarının tedavisi | |
CA2451680A1 (en) | Human dr4 antibodies and uses thereof | |
DK1558730T3 (da) | Inhibitorresistent HCV-NS3-protease | |
WO2002055098A3 (en) | Latency associated peptide for providing latency to pharmaceutically active proteins | |
EA200500300A1 (ru) | Цитотоксические агенты, содержащие новые сильнодействующие таксаны, и их терапевтическое применение | |
WO2004030622A3 (en) | Method of isolation and self-assembly of small protein particles from blood and other biological materials | |
WO2004054607A3 (de) | Stabile therapeutische proteine | |
AU7525398A (en) | Inhibitors for urokinase receptor | |
DE69333952D1 (de) | Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen. | |
EP1265073A3 (en) | Methods for determining plasma free drug concentration | |
WO2002068475A3 (es) | Composicion farmaceutica de fragmentos f(ab)2 de anticuerpos y un proceso para su preparacion | |
EP1527178A4 (en) | NEW CLASS II CYTOKIN RECEPTORS AND ITS USES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |